Almirall Signs an In-License Agreement with 23andMe for Multiple Inflammatory Diseases

 Almirall Signs an In-License Agreement with 23andMe for Multiple Inflammatory Diseases

Shots:

  • 23andMe has out-license its bispecific mAb targeted to block three members of the IL-36 cytokine subfamily & will leverage Almirall’s expertise in medical dermatology & accelerating the development the preclinical program
  • Almirall to get exclusive WW rights to develop and commercialize the mAbs and will also be responsible for clinical studies. The focus of the agreement is to strengthen ALmirall’s early-stage research portfolio
  • IL-36 is an IL-1 cytokine family targeted for associated with multiple inflammatory diseases, including various dermatological conditions

Click here to read full press release/ article | Ref: Almirall | Image: Twitter

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post